Back to results
US 5,677,336 AGranted
Non-steroid androgen receptor antagonist compounds and methods
AssigneeLigand Pharmaceuticals Incorporated
InventorsTodd K. Jones, Lawrence G. Hamann, Luc Farmer, Michael G. Johnson, Mark E. Goldman
Life of this patent
Estimating the term…
Abstract
Non-steroidal compounds which are high affinity, high specificity ligand antagonists for the androgen receptor are disclosed. Also disclosed are methods for employing the disclosed compounds for modulating processes mediated by the androgen receptor and for treating patients requiring androgen receptor antagonist therapy.
Claims4
A method of antagonizing androgen activity comprising the in vivo administration of one or more of the compounds exhibiting activity as an androgen receptor antagonist having the formulae:
- ##STR13## wherein:
- the dotted lines in the structure depict optional double bonds;
- X is carbon;
- R.sub.1 is R.sub.17, --OR.sub.17, --N(R.sub.17'), --SR.sub.17, fluorine, chlorine, bromine, or --NO.sub.2 ;
- R.sub.17 and (R.sub.17'), each independently, are hydrogen, saturated or unsaturated C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.7 cycloalkyl, C.sub.5 -C.sub.7 aryl, or C.sub.7 aralkyl, said alkyl groups being branched or straight-chain;
- R.sub.2 is --NO.sub.2, --N(OH)R.sub.17, fluorine, chlorine, bromine, iodine, R.sub.17, --N(R.sub.17) (R.sub.17'), --SR.sub.17, --S(O).sub.2 --R.sub.17, --CH.sub.2 OH, --C(O)--H, --C(O)CH.sub.3, --C(O)--OCH.sub.3, --CH.dbd.CH.sub.2, --CH.dbd.CH--C(O) --C(O).sub.3, or R.sub.18 ;
- R.sub.18 and (R.sub.18'), each independently, are hydrogen, saturated or unsaturated C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.7 cycloalkyl, C.sub.5 -C.sub.7 aryl, or C.sub.7 aralkyl, said alkyl groups being branched or straight-chain which optionally may contain hydroxyl, aldehyde, ketone, nitrile, or ester groups;
- R.sub.3 is R.sub.17 or --OR.sub.17 ;
- R.sub.4 is hydrogen, --OR.sub.17, --OC(O)R.sub.17, --OC(O)OR.sub.17, --OC(O)N(R.sub.17) (R.sub.17), --OS(O).sub.2 R.sub.17, or --OS(O)--R.sub.17, except that R.sub.1, R.sub.2, R.sub.3, and R.sub.4 cannot all be hydrogen, and R.sub.1 cannot be OCH.sub.3 when R.sub.2, R.sub.3, and R.sub.4 are each hydrogen;
- R.sub.5 is hydrogen;
- R.sub.6 is R.sub.17 ;
- R.sub.7 R.sub.8, each independently, are R.sub.18, or R.sub.7 and R.sub.8 together are a carbocyclic 3-8 member ring, but R.sub.7 and R.sub.8 cannot both be hydrogen in the second of the two above structures;
- R.sub.9 and R.sub.10, each independently, are chlorine, bromine, or R.sub.17, or R.sub.9 and R.sub.10 combined are .dbd.O, except when X.dbd.O, R.sub.9 and R.sub.10 are not present, and except that neither R.sub.9 or R.sub.10 can be bromine when R.sub.1 is methoxy, R.sub.2 is bromo, R.sub.3 is hydrogen, R.sub.4 is hydroxy, R.sub.5 and R.sub.6 are hydrogen, and R.sub.7 and R.sub.8 are methyl, R.sub.11 -R.sub.14 are hydrogen, and R.sub.15 and R.sub.16 together are methylene;
- R.sub.11 and R.sub.12, each independently, are --OR.sub.17, R.sub.18, are .dbd.O, or are .dbd.CH.sub.2, except when R.sub.11 is attached to an sp.sup.2 carbon atom in the ring, then R.sub.12 is not present and R.sub.11 is R.sub.18,
- or R.sub.11 and R.sub.13 together are joined in a carbocyclic 3-8 member ring or are --O-- to form an expoxide;
- R.sub.13 and R.sub.14, each independently, are --OR.sub.17 or R.sub.18, except when R.sub.13 is attached to an sp.sup.2 carbon atom in the ring, then R.sub.14 is not present and R.sub.17 is --OR.sub.17 or R.sub.18 ;
- R.sub.15 and R.sub.16, each independently, are R.sub.18 except that R.sub.15 and R.sub.6 cannot both be H, or R.sub.15 and R.sub.16 together are --CH.sub.2 --O-- forming an epoxide, or R.sub.15 and R.sub.16 combined are .dbd.O or .dbd.C(R.sub.18)(R.sub.18'), except when R.sub.15 and R.sub.16 combined are .dbd.O then R.sub.7 and R.sub.8 cannot both be hydrogen, and except when R.sub.15 is attached to an sp.sup.2 carbon atom in the ring, then R.sub.16 is not present, or R.sub.15 and R.sub.16 together are joined in a carbocyclic 3-8 member ring.
14 more elements
A method for treating a mammalian subject requiring androgen receptor antagonist therapy comprising administering to such subject a pharmaceutically effective amount of a compound exhibiting activity as an androgen receptor antagonist having the formulae:
- ##STR14## wherein:
- the dotted lines in the structure depict optional double bonds;
- X is carbon;
- R.sub.1 is R.sub.17, --OR.sub.17, --N(R.sub.17)(R.sub.17'), --SR.sub.17, fluorine, chlorine, bromine, or --NO.sub.2,
- R.sub.17 and (R.sub.17'), each independently, are hydrogen, saturated or unsaturated C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.7 cycloalkyl, C.sub.5 -C.sub.7 aryl, or C.sub.7 aralkyl, said alkyl groups being branched or straight-chain;
- R.sub.2 is --NO.sub.2, --N(OH) R.sub.17, fluorine, chlorine, bromine, iodine, R.sub.17, --N(R.sub.17) (R.sub.17'), --SR.sub.17, --S(O)--R.sub.17, --S(O).sub.2 --R.sub.17, --CH.sub.2 OH, --C(O)--H, --C(O)CH.sub.3, --C(O)--OCH.sub.3, --CH.dbd.CH.sub.2, --CH.dbd.CH--C(O)--OCH.sub.3, or R.sub.18 ;
- R.sub.18 and (R.sub.18'), each independently, are hydrogen, saturated or unsaturated C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.7 cycloalkyl, C.sub.5 -C.sub.7 aryl, or C.sub.7 aralkyl, said alkyl groups being branched or straight-chain which optionally may contain hydroxyl, aldehyde, ketone, nitrile, or ester groups;
- R.sub.3 is R.sub.17 or --OR.sub.17 ;
- R.sub.4 is hydrogen, --OR.sub.17, --OC(O)R.sub.17, --OC(O)OR.sub.17, --OC(O)N(R.sub.17) (R.sub.17'), --OS(O).sub.2 R.sub.17, or --OS(O)--R.sub.17, except that R.sub.1, R.sub.2, R.sub.3, and R.sub.4 cannot all be hydrogen, and R.sub.1 cannot be OCH.sub.3 when R.sub.2, R.sub.3, and R.sub.4 are each hydrogen;
- R.sub.5 is hydrogen;
- R.sub.6 is R.sub.17 ;
- R.sub.7 and R.sub.8, each independently, are R.sub.18, or R.sub.7 and R.sub.8 together are a carbocyclic 3-8 member ring, but R.sub.7 and R.sub.8 cannot both be hydrogen in the second of the two above structures;
- R.sub.9 and R.sub.10, each independently, are chlorine, bromine, or R.sub.17 or R.sub.9 and R.sub.10 combined are .dbd.O, except when X.dbd.O, R.sub.9 and R.sub.10 are not present, and except that neither R.sub.9 or R.sub.10 can be bromine and R.sub.1 is methoxy, R.sub.2 is bromo, R.sub.3 is hydrogen, R.sub.4 is hydroxy, R.sub.5 and R.sub.6 are hydrogen, and R.sub.7 and R.sub.8 are methyl, R.sub.11 -R.sub.14 are hydrogen, and R.sub.15 and R.sub.16 together are methylene;
- R.sub.11 and R.sub.12, each independently, are --OR.sub.17, R.sub.18, are .dbd.O, or are .dbd.CH.sub.2, except when R.sub.11 is attached to an sp.sup.2 carbon atom in the ring, then R.sub.12 is not present and R.sub.11 is R.sub.18,
- or R.sub.11 and R.sub.13 together are joined in a carbocyclic 3-8 member ring or are --O-- to form an expoxide;
- R.sub.13 and R.sub.14, each independently, are --OR.sub.17 or R.sub.18, except when R.sub.13 is attached to an sp.sup.2 carbon atom in the ring, then R.sub.14 is not present and R.sub.13 is --OR.sub.17 or R.sub.18 ;
- R.sub.15 and R.sub.16, each independently, are R.sub.18 except that R.sub.15 and R.sub.16 cannot both be H, or R.sub.15 and R.sub.16 together are --CH.sub.2 --O-- forming an epoxide, or R.sub.15 and R.sub.16 combined are .dbd.O or .dbd.C(R.sub.18)(R.sub.18'), except when R.sub.15 and R.sub.16 combined are .dbd.O then R.sub.7 and R.sub.8 cannot both be hydrogen, and except when R.sub.15 is attached to an sp.sup.2 carbon atom in the ring, then R.sub.16 is not present, or R.sub.15 and R.sub.16 together are joined in a carbocyclic 3-8 member ring.
14 more elements
A method for modulating a process mediated by androgen receptors comprising causing said process to be conducted in the presence of at least one compound exhibiting activity as an androgen receptor antagonist having the formulae:
- ##STR15## wherein:
- the dotted lines in the structure depict optional double bonds;
- X is carbon;
- R.sub.1 is R.sub.17, --OR.sub.17, --N(R.sub.17)(R.sub.17'), --SR.sub.17, fluorine, chlorine, bromine, or --NO.sub.2 ;
- R.sub.17 and (R.sub.17'), each independently, are hydrogen, saturated or unsaturated C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.7 cycloalkyl, C.sub.5 -C.sub.7 aryl, or C.sub.7 aralkyl, said alkyl groups being branched or straight-chain;
- R.sub.2 is --NO.sub.2, --N(OH)R.sub.17, fluorine, chlorine, bromine, iodine, R.sub.17, --N(R.sub.17) (R.sub.17'), --SR.sub.17, --S(O)--R.sub.17, --S(O).sub.2 --R.sub.17, --CH.sub.2 OH, --C(O)--H, --C(O)CH.sub.3, --C(O)--OCH.sub.3, --CH.dbd.CH.sub.2, --CH.dbd.CH--C(O)--OCH.sub.3, or R.sub.18 ;
- R.sub.18 and (R.sub.18'), each independently, are hydrogen, saturated or unsaturated C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.7 cycloalkyl, C.sub.5 -.sub.7 aryl, or C.sub.7 aralkyl, said alkyl groups being branched or straight-chain which optionally may contain hydroxyl, aldehyde, ketone, nitrile, or ester groups;
- R.sub.3 is R.sub.17 or --OR.sub.17 ;
- R.sub.4 is hydrogen, --OR.sub.17, --OC(O)R.sub.17, --OC(O)OR.sub.17, --OC(O)N(R.sub.17) (R.sub.17'), --OS(O).sub.2 R.sub.17, or --OS(O)--R.sub.17, except that R.sub.1, R.sub.2, R.sub.3, and R.sub.4 cannot all be hydrogen, and R.sub.1 cannot be OCH.sub.3 when R.sub.2, R.sub.3, and R.sub.4 are each hydrogen;
- R.sub.5 is hydrogen;
- R.sub.6 is R.sub.17 ;
- R.sub.7 and R.sub.8, each independently, are R.sub.18, or R.sub.7 and R.sub.8 together are a carbocyclic 3-8 member ring, but R.sub.7 and R.sub.8 cannot both be hydrogen in the second of the two above structures;
- R.sub.9 and R.sub.10, each independently, are chlorine, bromine, or R.sub.17, or R.sub.9 and R.sub.10 combined are .dbd.O, except when X.dbd.O, R.sub.9 and R.sub.10 are not present, and except that neither R.sub.9 or R.sub.10 can be bromine when R.sub.1 is methoxy, R.sub.2 is bromo, R.sub.3 is hydrogen, R.sub.4 is hydroxy, R.sub.5 and R.sub.6 are hydrogen, and R.sub.7 and R.sub.8 are methyl, R.sub.11 -R.sub.14 are hydrogen, and R.sub.15 and R.sub.16 together are methylene;
- R.sub.11 and R.sub.12, each independently, are --OR.sub.17, R.sub.18, are .dbd.O, or are .dbd.CH.sub.2, except when R.sub.11 is attached to an sp.sup.2 carbon atom in the ring, then R.sub.12 is not present and R.sub.11 is R.sub.18,
- or R.sub.11 and R.sub.13 together are joined in a carbocyclic 3-8 member ring or are --O-- to form an expoxide;
- R.sub.13 and R.sub.14, each independently, are --OR.sub.17 or R.sub.18, except when R.sub.13 is attached to an sp.sup.2 carbon atom in the ring, then R.sub.14 is not present and R.sub.13 is --OR.sub.17 or R.sub.18 ;
- R.sub.15 and R.sub.16, each independently, are R.sub.18 except that R.sub.15 and R.sub.16 cannot both be H, or R.sub.15 and R.sub.16 together are --CH.sub.2 --O-- forming an epoxide, or R.sub.15 and R.sub.16 combined are .dbd.O or .dbd.C(R.sub.18)(R.sub.18'), except when R.sub.15 and R.sub.16 combined are .dbd.O then R.sub.7 and R.sub.8 cannot both be hydrogen, and except when R.sub.15 is attached to an sp.sup.2 carbon atom in the ring, then R.sub.16 is not present, or R.sub.15 and R.sub.16 together are joined in a carbocyclic 3-8 member ring.
14 more elements
A method for modulating a process mediated by androgen receptors comprising administering to a mammalian subject an amount, effective to moderate said process mediated by said androgen receptors, of a compound exhibiting activity as an androgen receptor antagonist having the formulae:
- ##STR16## wherein:
- the dotted lines in the structure depict optional double bonds;
- X is carbon;
- R.sub.1 is R.sub.17, --OR.sub.17, --N(R.sub.17) (R.sub.17'), --SR.sub.17, fluorine, chlorine, bromine, or --NO.sub.2 ;
- R.sub.17 and (R.sub.17'), each independently, are hydrogen, saturated or unsaturated C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.7 cycloalkyl, C.sub.5 -C.sub.7 aryl, or C.sub.7 aralkyl, said alkyl groups being branched or straight-chain;
- R.sub.2 is --NO.sub.2, --N(OH)R.sub.17, fluorine, chlorine, bromine, iodine, R.sub.17, --N(R.sub.17) (R.sub.17'), --SR.sub.17, --S(O)--R.sub.17, --S(O).sub.2 --R.sub.17, --CH.sub.2 OH, --C(O)--H, --C(O)CH.sub.3, --C(O)--OCH.sub.3, --CH.dbd.CH.sub.2, --CH.dbd.CH--C(O)--OCH.sub.3, or R.sub.18 ;
- R.sub.18 and (R.sub.18'), each independently, are hydrogen, saturated or unsaturated C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.7 cycloalkyl, C.sub.5 -C.sub.7 aryl, or C.sub.7 aralkyl, said alkyl groups being branched or straight-chain which optionally may contain hydroxyl, aldehyde, ketone, nitrile, or ester groups;
- R.sub.3 is R.sub.17 or --OR.sub.17 ;
- R.sub.4 is hydrogen, --OR.sub.17, --OC(O)R.sub.17, --OC(O)OR.sub.17, --OC(O)N(R.sub.17) (R.sub.17'), --OS(O).sub.2 R.sub.17, or --OS(O)--R.sub.17, except that R.sub.1, R.sub.2, R.sub.3, and R.sub.4 cannot all be hydrogen, and R.sub.1 cannot be OCH.sub.3 when R.sub.2, R.sub.3, and R.sub.4 are each hydrogen;
- R.sub.5 is hydrogen;
- R.sub.6 and R.sub.17 ;
- R.sub.7 and R.sub.8, each independently, are R.sub.18, or R.sub.7 and R.sub.8 together are a carbocyclic 3-8 member ring, but R.sub.7 and R.sub.8 cannot both be hydrogen in the second of the two above structures;
- R.sub.9 and R.sub.10, each independently, are chlorine, bromine, or R.sub.17, or R.sub.9 and R.sub.10 combined are .dbd.O, except when X.dbd., R.sub.9 and R.sub.10 are not present, and except that neither R.sub.9 or R.sub.10 can be bromine when R.sub.1 is methoxy, R.sub.2 is bromo, R.sub.3 is hydrogen, R.sub.4 is hydroxy, R.sub.5 and R.sub.6 are hydrogen, and R.sub.7 and R.sub.8 are methyl, R.sub.11 -R.sub.14 are hydrogen, and R.sub.15 and R.sub.16 together are methylene;
- R.sub.11 and R.sub.12, each independently, are --OR.sub.17, R.sub.18, are .dbd.O, or are .dbd.CH.sub.2, except when R.sub.11 is attached to an sp.sup.2 carbon atom in the ring, then R.sub.12 is not present and R.sub.11 is R.sub.18,
- or R.sub.11 and R.sub.13 together are joined in a carbocyclic 3-8 member ring or are --O-- to form an expoxide;
- R.sub.13 and R.sub.14, each independently, are --OR.sub.17 or R.sub.18, except when R.sub.13 is attached to an sp.sup.2 carbon atom in the ring, then R.sub.14 is not present and R.sub.13 is --OR.sub.17 or R.sub.18 ;
- R.sub.15 and R.sub.16, each independently, are R.sub.18 except that R.sub.15 and R.sub.16 cannot both be H, or R.sub.15 and R.sub.16 together are --CH.sub.2 --O-- forming an epoxide, or R.sub.15 and R.sub.16 combined are .dbd.O or .dbd.C(R.sub.18) (R.sub.18'), except when R.sub.15 and R.sub.16 combined are .dbd.O then R.sub.7 and R.sub.8 cannot both be hydrogen, and except when R.sub.15 is attached to an sp.sup.2 carbon atom in the ring, then R.sub.16 is not present, or R.sub.15 and R.sub.16 together are joined in a carbocyclic 3-8 member ring.
14 more elements
Dependencies are inferred from the claim text.